Sumitomo Corporation Partners with AI Startup AiRato to Revolutionize Cancer Radiation Therapy Planning
核心洞察
Sumitomo Corporation has invested in AiRato Inc. (搜索), a Japanese startup that developed AI-powered software to dramatically reduce cancer radiation therapy planning time from six hours to just 20 minutes.
The partnership includes an exclusive overseas distribution agreement for AiRato's radiation therapy planning support software, with plans to begin distribution across Asia in 2026.
AiRato's AI technology, developed through collaboration with 15 Japanese university hospitals, can identify tumors and radiation fields from CT images using machine learning trained on vast clinical datasets.
Sumitomo Corporation has made a strategic investment in AiRato Inc. (搜索), a Japanese startup that has developed artificial intelligence software capable of reducing cancer radiation therapy planning time from six hours to just 20 minutes. The partnership includes an exclusive overseas distribution agreement for AiRato's radiation therapy planning support software, with Sumitomo Corporation planning to begin distribution across Asia in 2026 following regulatory compliance efforts.
Revolutionary AI Technology Transforms Treatment Planning
AiRato's AI planning software addresses a critical bottleneck in modern cancer care. Large hospitals in medically advanced countries including Japan have increasingly adopted intensity-modulated radiation therapy (IMRT) for cancer treatment, which minimizes damage to healthy tissue while delivering targeted radiation to cancer cells, reducing patient burden compared to conventional radiation therapy.
However, creating a treatment plan for IMRT presents significant challenges, requiring up to six hours per case due to the need for precise identification of tumor location from CT images and detailed calculation of radiation intensity and targeting. This intensive process places a heavy workload on doctors and medical staff.
AiRato's breakthrough technology applies AI trained on a vast dataset of past clinical cases to identify tumors and radiation fields from CT images, cutting treatment planning time to just 20 minutes. This represents an 18-fold improvement in efficiency for physicians and medical staff engaged in IMRT.
Strong Clinical Foundation and University Collaboration
The startup was founded on research conducted at the Graduate School of Medicine at Tohoku University and has developed its technology through collaboration with approximately 15 university hospitals in Japan that actively use IMRT. This extensive clinical experience has advanced both the sophistication and practical application of the AI-powered treatment planning software.
AiRato Inc. (搜索), established in 2022 and headquartered in Sendai City, Miyagi Prefecture, is led by CEO Yuto Kimura and CTO Noriyuki Kadoya. The company focuses specifically on improving outcomes and streamlining operations in cancer radiation therapy through AI technology.
Strategic Expansion Across Asia
Sumitomo Corporation's Life Sciences Strategic Business Unit brings decades of pharmaceutical industry experience to the partnership, having been involved in pharmaceutical-related businesses since the 1970s. The company's activities include supporting drug discovery and development, supplying raw materials, and providing services such as marketing, sales, and contract manufacturing.
Under its current Medium-Term Management Plan 2026, Sumitomo Corporation has identified the provision of medical technology support to healthcare providers as a new strategic pillar. This initiative builds on the company's previous success with AOI Biosciences Inc. (搜索), a Japanese startup providing testing services for infertility and recurrent pregnancy loss, for which Sumitomo Corporation also secured an exclusive overseas distribution agreement.
AOI's testing services are currently in use at hospitals in Malaysia, with collaborative research underway in Indonesia and South Korea, demonstrating Sumitomo Corporation's proven ability to expand Japanese medical technologies throughout Asia.
Market Impact and Future Outlook
The partnership represents a significant advancement in addressing the operational challenges facing cancer treatment centers worldwide. By dramatically reducing the time required for radiation therapy planning, AiRato's technology has the potential to increase treatment capacity and reduce wait times for cancer patients while alleviating the workload burden on medical professionals.
Sumitomo Corporation plans to leverage its global network and regulatory expertise to ensure compliance across Asian markets, positioning the technology for widespread adoption in the region's healthcare systems. The company will continue to combine its expertise and global reach in healthcare with advanced technologies from Japanese medical startups, expanding its medical support business worldwide.